Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL

September 2nd 2022

Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.

SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations

September 1st 2022

The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.

Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma

September 1st 2022

Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.

Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups

September 1st 2022

Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.

Future Directions in the Management of Immune Thrombocytopenia

September 1st 2022

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.

CTCL Is Rare, Incurable, and Potentially Lethal in Advanced Stages

August 31st 2022

Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased steadily since the 1970s.

Approval Sought for Tafasitamab/Lenalidomide Combo in R/R DLBCL in Hong Kong

August 31st 2022

The Hong Kong Special Administrative Region’s Department of Health has accepted for review a biologics license application seeking the approval of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Frontline Pivekimab Sunirine Demonstrates Significant Activity in Blastic Plasmacytoid Dendritic Cell Neoplasm

August 31st 2022

First-line treatment with pivekimab sunirine generated responses with favorable tolerability in patients with blastic plasmacytoid dendritic cell neoplasm, according to data from the phase 2 CADENZA trial.

Women in Oncology: Prioritization and Passionate Legacies

August 30th 2022

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

FDA Allows Trial Enrollment to Resume for Single-Agent Emavusertib in AML/MDS

August 30th 2022

The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS

August 30th 2022

Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.

Daiichi Sankyo Submits sNDA for Quizartinib in Newly Diagnosed FLT3-ITD+ AML in Japan

August 30th 2022

Daiichi Sankyo submitted a supplemental new drug application to Japan’s Ministry of Health, Labor, and Welfare for the use of quizartinib in patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia.

Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

August 29th 2022

The combination of plinabulin and pegfilgrastim was well tolerated patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation and who have received a high dose of melphalan.

EU Approves Asciminib for Ph+ CML in Chronic Phase After 2 or More TKIs

August 29th 2022

The European Commission has approved asciminib for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who received prior treatment with at least 2 TKIs

Using Multidisciplinary Care to Optimize Outcomes in GVHD

August 29th 2022

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Daratumumab Plus RVd Improves Clinical Outcomes in Transplant-Eligible, Newly Diagnosed Multiple Myeloma

August 28th 2022

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma

August 28th 2022

Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.

Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data

August 27th 2022

Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.

Post-Transplant Carfilzomib Plus Lenalidomide/Dexamethasone Provides Superior PFS Benefit Over Lenalidomide in Myeloma

August 26th 2022

Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.